George Naumov

Company: RS Oncology Ltd

Job title: COO

Seminars:

Clinical Development of RSO-021, a Novel Covalent Inhibitor Targeting Mitochondrial PRX3 3:30 pm

What is the optimal profile of a covalent drug targeting PRX3, considering target engagement, PKPD, safety and tolerability? How to design and implement clinical trials to validate the safety, efficacy, and specificity of covalent modification strategies and with what biomarkers? How to predict and mitigate the long-term effects and potential for cumulative toxicity of covalent…Read more

day: Conference Day Two